Renal drug dosing recommendations: Evaluation of product information for brands of the same drug

Internal Medicine Journal

Volumn 44, Issue 6, 2014, Pages 591-596

  Khanal, A ^a   Peterson, G M ^a   Castelino, R L ^a   Jose, M D ^b  

^a Pharmacy Board of Tasmania   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Drug dosing; GFR; Glomerular filtration rate; Kidney function; Product information; Renal impairment

Indexed keywords

ALENDRONIC ACID; ALLOPURINOL; ALPRAZOLAM; AMFEBUTAMONE; AMISULPRIDE; ATENOLOL; BACLOFEN; BISOPROLOL; COLCHICINE; DIGOXIN; ENALAPRIL; ETIRACETAM; GABAPENTIN; GALANTAMINE; GENERIC DRUG; GLIBENCLAMIDE; GLIMEPIRIDE; HYDROMORPHONE; LITHIUM; MEMANTINE; METFORMIN; MORPHINE; OXYCODONE; PRAMIPEXOLE; RANITIDINE; SPIRONOLACTONE; TOPIRAMATE; TRAMADOL; VENLAFAXINE; ANTIDIABETIC AGENT; ANTIGOUT AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DRUG; NARCOTIC AGENT; PSYCHOTROPIC AGENT;

ARTICLE; CREATININE CLEARANCE; DRUG DOSE REGIMEN; DRUG INFORMATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MODERATE RENAL IMPAIRMENT; PATIENT CARE; PRIORITY JOURNAL; SEVERE RENAL IMPAIRMENT; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONTRAINDICATIONS; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECTS; DRUG LABELING; EVALUATION STUDY; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TEST; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ALENDRONATE; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG LABELING; DRUGS, GENERIC; GLOMERULAR FILTRATION RATE; GOUT SUPPRESSANTS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; NARCOTICS; PHARMACEUTICAL PREPARATIONS; PSYCHOTROPIC DRUGS; RANITIDINE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84904615598     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12446     Document Type: Article

References (24)

1. Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacists' interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant 2012; 27: 276-292.
2. Bell JS, Blacker N, Leblanc VT, Alderman CP, Phillips A, Rowett D etal. Prescribing for older people with chronic renal impairment. Aust Fam Physician 2013; 42: 24-28.
3. Olyaei AJ, Steffl JL. A quantitative approach to drug dosing in chronic kidney disease. Blood Purif 2011; 31: 138-145.
4. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989; 321: 303-309.
5. MIMS Australia. 2012 MIMS Annual, 26th edn. Sydney: Medi-Media Australia; 2012.
6. Stockigt JR. Barriers in the quest for quality drug information: salutary lessons from TGA-approved sources for thyroid-related medications. Med J Aust 2007; 186: 76-79.
7. Mallows J, Chan B, Graudins A. Quality of poisoning management advice in the Monthly Index of Medical Specialties Annual. Emerg Med Australas 2005; 17: 511-519.
8. Tan E, Cranswick NE, Rayner CR, Chapman CB. Dosing information for paediatric patients: are they really 'therapeutic orphans'?. Med J Aust 2003; 179: 195-198.
9. Veterans' MATES. (Veterans' Medicines Advice and Therapeutics Education Services). Therapeutic Brief 30 - Know your patient's renal function - an important prescribing consideration. Department of Veterans Affairs 2012 [cited 2012 Sep 13]. Available from URL: https://www.veteransmates.net.au/VeteransMATES/documents/module_materials/M30_TherBrief.pdf
10. MIMS Australia. eMIMS version 5.01.0111. Sydney: CMP Medica Australia; 2006.
11. Ibrahim S, Honig P, Huang SM, Gillespie W, Lesko LJ, Williams RL. Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives. J Clin Pharmacol 2000; 40: 31-38.
12. Dowling TC, Matzke GR, Murphy JE, Burckart GJ. Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. Pharmacotherapy 2010; 30: 776-786.
13. U.S. Food and Drug Administration. Guidance for Industry: pharmacokinetics in patients with impaired renal function - study design, data analysis and impact on dosing and labeling. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) 1998 [cited 2013 Jun 6]. Available From URL: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM204959.pdf
14. European Medicines Agency. Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function 2004 [cited 2013 May 6]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003123.pdf
15. European Medicines Agency. Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function 2004 [cited 2013 May 6]. Available from URL: http://www.tga.gov.au/pdf/euguide/ewp022502en.pdf
16. Newman AB, Ferrucci L. Call for papers: aging versus disease. J Gerontol A Biol Sci Med Sci 2009; 64: 1163-1164.
17. El-husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A. Baclofen toxicity in patients with advanced nephropathy: proposal for new labeling. Am J Nephrol 2011; 34: 491-495.
18. Koch KM, Liu M, Davis IM, Shaw S, Yin Y. Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment. Eur J Clin Pharmacol 1997; 52: 229-234.
19. Dixon JS, Borg-Costanzi JM, Langley SJ, Lacey LF, Toon S. The effect of renal function on the pharmacokinetics of ranitidine. Eur J Clin Pharmacol 1994; 46: 167-171.
20. Rossi S. Australian Medicines Handbook Adelaide, South Australia, 2012.
21. Joint Formulary Committee. British National Formulary, 48th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2012. [cited 2013 May 6]. Available from URL: http://www.bnf.org/bnf/
22. Khanal A, Castelino RL, Peterson GM, Jose MD. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources? Intern Med J 2014; 44: 77-85.
23. Stockigt JR. The quality of medication information in Australia: the need for more clinical expertise and accountability. Med J Aust 2009; 190: 110-111.
24. eMIMS 5.0. Product information for thyroxine, liothyronine, carbimazole and propylthiouracil. [cited 2013 May 1]. Available from URL: http://www.mims.com.au